Hemispherx Biopharma Inc (HEB): Thomas K. Equels , CEO of Hemispherx Biopharma Inc purchased 171,000 shares on Jun 29, 2016. The Insider buying transaction was reported by the company on Jul 1, 2016 to the Securities and Exchange Commission. The shares were purchased at $0.12 per share for a total value of $20,424.30 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Mar 21, 2016, Thomas K. Equels (CEO) purchased 30,000 shares at $0.13 per share price.On Aug 20, 2015, William A Carter (CEO) purchased 25,000 shares at $0.18 per share price.
Hemispherx BioPharma Inc: On Wednesday, Jun 29, 2016 heightened volatility was witnessed in Hemispherx BioPharma Inc which led to swings in the share price. The shares opened for trading at $0.1134 and hit $0.1202 on the upside , eventually ending the session at $0.1161, with a gain of 2.38% or 0.0027 points. The heightened volatility saw the trading volume jump to 5,55,117 shares. The 52-week high of the share price is $0.217 and the company has a market cap of $29 M . The 52-week low of the share price is at $0.0604.
Hemispherx Biopharma Inc. (Hemispherx) is a specialty pharmaceutical company engaged in the clinical development of new drugs therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The Company’s flagship products include Alferon N Injection and Ampligen. Alferon N Injection is approved for the use in intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older. Ampligen is an experimental drug undergoing clinical development for the treatment of CFS (Chronic Fatigue Syndrome). The Company’s Alferon LDO (Low Dose Oral) is an experimental liquid natural interferon for oral administration.